ResMed Inc. has agreed to sell its MatrixCare healthcare software business to Frazier Healthcare Partners for $490 million in cash, reversing part of a diversification strategy that began when the medical-device company acquired MatrixCare for $750 million in 2018. The transaction is expected to close during the first quarter of Resmed’s fiscal year 2027, subject
Roche Holding AG has discontinued development of tominersen and RG6496, removing two investigational huntingtin-lowering medicines from its neurology pipeline after separate setbacks emerged almost simultaneously. The Phase 2 GENERATION HD2 trial showed that tominersen lowered important biological markers but did not meaningfully slow clinical decline, while the Phase 1 POINT-HD study of RG6496 was halted
Elucid’s AI-PREDICT study will test whether CCTA plaque analysis can identify the coronary lesions most likely to cause a heart attack.
Biocon’s new Yesafili studies add switching and subgroup evidence ahead of a planned U.S. launch in the competitive aflibercept market.
Confluence Genetics launches Cas-CLEAR, a Cas12a2 CRISPR platform designed to kill mutation-bearing cancer cells. Explore the evidence and risks.
Delcath has dosed the first patient in the DELUMA Phase 2 trial, testing HEPZATO for liver-dominant HER2-negative metastatic breast cancer.
Auxilium Biotechnologies bioprints kidney and liver tissues in orbit, advancing microgravity biofabrication while major clinical hurdles remain.
The United States Food and Drug Administration (FDA) has approved Sanofi’s Sarclisa Escena for subcutaneous administration through the CirCLIQ on-body injector, creating the first FDA-authorised anticancer treatment that can be delivered using a wearable injector. The regulator approved the fixed 1,400-milligram dose on July 9, 2026 for several multiple myeloma treatment combinations already supported by
Teva gains broad rights to PB018 as Polpharma Biologics advances an Ocrevus biosimilar into clinical development for multiple sclerosis.
Rani Therapeutics Holdings, Inc. and PegBio Co., Ltd. have formed a research and development collaboration to evaluate whether several injectable obesity and metabolic disease candidates can be delivered through Rani Therapeutics’ swallowable RaniPill platform. The partners plan to screen oral formulations, complete preclinical development and select the most promising programmes for possible advancement into human